Your basket is currently empty!
Cabozantinib Yields Similar QoL Outcomes to Everolimus in RCC
Patients with advanced renal cell carcinoma had an improved time to deterioration (TTD) and similar quality of ...
News Archive
Everolimus
Cabozantinib Bests Everolimus in RCC with Bone Metastases
Cabozantinib (Cabometyx) was more effective than everolimus (Afinitor) in patients with advanced renal cell ...
New treatment option: Cabozantinib is now available for use in the NHS for advanced kidney cancer patients
Kidney Cancer UK is delighted that National Institute for Health and Care Excellence (NICE) has recommended the ...
ASPEN Compares Sunitinib, Everolimus in Metastatic Non-Clear Cell Renal Cell Carcinoma
Clinicians now have a better picture of what may be the optimal first-line therapy for patients with metastatic ...
Delisting of Everolimus by the Cancer Drug Fund
Kidney Cancer UK has added its voice to call for an overhaul of the delisting process of essential cancer drugs by ...
Scottish Medicines Consortium recommends Everolimus
Kidney Cancer Scotland welcomes the news today that the Scottish Medicines Consortium (SMC) has issued a positive ...
An Open Label Randomized Phase II Study Comparing Azd2014 Versus Everolimus In Patients With Advanced Metastatic Renal Cancer And Progression On VEGF Targeted Therapy
The study is a randomised trial allowing us to quantify the benefit and potential for further development of ...
An Open Label Randomized Phase II Study Comparing Azd2014 Versus Everolimus In Patients With Advanced Metastatic Renal Cancer And Progression On VEGF Targeted Therapy
The study is a randomised trial allowing us to quantify the benefit and potential for further development of ...
